• AbbVie reported positive topline Phase 3 results for epcoritamab with lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.
• The study met its primary goal, showing longer time without disease worsening versus the R-GemOx regimen.
• Data have not yet been presented; results are slated for a future medical meeting.
• AbbVie plans regulatory discussions, supporting a potential label expansion for the subcutaneous bispecific antibody franchise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CG93669) on June 29, 2026, and is solely responsible for the information contained therein.